# Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

> **NCT01636908** · NA · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 43 (actual)

## Conditions studied

- Cancer
- Advanced Solid Tumors

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Sorafenib
- **DRUG:** Erlotinib
- **DRUG:** Everolimus
- **DRUG:** Lapatinib
- **DRUG:** Dasatinib
- **DRUG:** Pazopanib
- **DRUG:** Vemurafenib
- **PROCEDURE:** tumor biopsy
- **PROCEDURE:** skin biopsy (optional)

## Key facts

- **NCT ID:** NCT01636908
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2018-01-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636908, "Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01636908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*